Vadadustat (MT-6548) Japan Phase 3 results for treatment of renal anemia to be presented at ASN Kidney Week 2019

1/2 October 25, 2019 Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office: Chuo-ku, Osaka; President & Representative Director: Masayuki Mitsuka, Ph.D.) today announced that Phase 3 results of Vadadustat (MT-6548) in Japan will be presented at American Society of Nephrology (ASN) Kidney Week 2019 from November 5 to November 10, 2019 in Washington DC. MTPC has submitted to the Ministry of Health, Labour and Welfare in Japan an application for the manufacturing and marketing approval of vadadustat (MT-6548). Our presentation is scheduled as follows: November 7, 2019 from 5:06 PM to 5:18 PM (Oral abstract session) Title; Randomized, Double-Blinded, Active-Controlled (Darbepoetin Alfa), Phase 3 Study of Vadadustat in CKD* Patients with Anemia on Hemodialysis in Japan *chronic kidney disease November 9, 2019 from 10:00 AM to 12:00 PM (Poster session) Title; Randomized, Open-Label, Active-Controlled (Darbepoetin Alfa), Phase 3 Study of Vadadustat for Treating Anemia in Non-Dialysis-Dependent CKD Patients in Japan Mitsubishi Tanabe Pharma Corporation Corporate Communications Department Media contacts: TEL:+81 6 6205 5119 Investor contacts: TEL:+81 6 6205 5110 Vadadustat (MT-6548) Japan Phase 3 results for treatment of renal anemia to be presented at ASN Kidney Week 2019 2/2 ◆Reference◆ About Vadadustat Vadadustat, in-licensed from Akebia Therapeutics, Inc., is an oral hypoxia- inducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in global Phase 3 development for the treatment of anemia due to chronic kidney disease. Vadadustat’s proposed mechanism of action is designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with increased production of HIF , which coordinates the interdependent processes of iron mobilization and erythropoietin production to increase red blood cell production and, ultimately, improve oxygen delivery. Vadadustat is an investigational therapy and is not approved by the U.S. Food and Drug Administration or any other regulatory authority.

The release as fetched from its publisher. tanabe-pharma.com ↗